Pfizer has made the decision to discontinue the clinical development program for danuglipron, an oral GLP-1 receptor agonist, being investigated for chronic weight management.

This time next year, you may be swapping your GLP-1 injections for easier and as-effective oral weight-loss medication. It's ...

Recursion said it earned its latest milestone payout by identifying differentiated, oral small molecule leads against a target the company described as a high interest immune cell target in immunology ...

Pfizer's PFE stock has risen 5% since it reported first-quarter results on April 29. While the company beat estimates for ...

Leerink Partnrs analysts have boosted Pfizer’s Q2 2025 earnings forecast from $0.52 to $0.57 per share, showing newfound ...